TSW
SGYP

Thompson Siegel & Walmsley’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

Thompson Siegel & Walmsley’s Portfolio SGYP Stock Details SGYP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-33,334
Closed -$155K – 921
2017
Q1 		$155K Sell
33,334
-82,100
-71% -$476K ﹤0.01% 467
2016
Q4 		$703K Sell
115,434
-23,800
-17% -$124K 0.01% 330
2016
Q3 		$767K Sell
139,234
-24,100
-15% -$113K 0.01% 314
2016
Q2 		$621K Sell
163,334
-25,350
-13% -$85.9K 0.01% 310
2016
Q1 		$521K Sell
188,684
-150
-0.1% -$543 0.01% 312
2015
Q4 		$1.07M Sell
188,834
-1,000
-0.5% -$6.1K 0.02% 271
2015
Q3 		$1.01M Sell
189,834
-40,200
-17% -$311K 0.02% 282
2015
Q2 		$1.91M Sell
230,034
-53,600
-19% -$260K 0.03% 254
2015
Q1 		$1.31M Sell
283,634
-2,900
-1% -$9.43K 0.02% 259
2014
Q4 		$874K Sell
286,534
-9,750
-3% -$28.8K 0.02% 291
2014
Q3 		$825K Buy
296,284
+29,500
+11% +$107K 0.02% 289
2014
Q2 		$1.09M Buy
266,784
+9,050
+4% +$38.5K 0.02% 278
2014
Q1 		$1.37M Buy
257,734
+48,901
+23% +$274K 0.03% 261
2013
Q4 		$1.16M Buy
208,833
+20,787
+11% +$89.6K 0.03% 278
2013
Q3 		$848K Buy
188,046
+34,019
+22% +$153K 0.02% 291
2013
Q2 		$656K Buy
+154,027
New +$774K 0.01% 306

Other funds holding SGYP

PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Thompson Siegel & Walmsley's SGYP Position: Q2 2017 in Review

Thompson Siegel & Walmsley sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q2 2017, closing a stake of 33,334 shares — an estimated $155K sold.

Thompson Siegel & Walmsley first reported a position in SGYP in Q2 2013 and held it in 16 quarters. The position peaked at $1.91M in Q2 2015. 146 funds tracked by Wall St. Rank hold SGYP as of Q2 2017.

  • Thompson Siegel & Walmsley reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q2 2017 after selling out during the quarter.
  • Thompson Siegel & Walmsley sold 33,334 Synergy Pharmaceuticals, Inc Common Stock shares in Q2 2017, an estimated $155K.
  • Thompson Siegel & Walmsley first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q2 2013 and held it in 16 quarters.
  • Thompson Siegel & Walmsley's Synergy Pharmaceuticals, Inc Common Stock position peaked at $1.91M in Q2 2015.
  • 146 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q2 2017.

Based on Thompson Siegel & Walmsley's 13F filing for Q2 2017, filed 9 Aug 2017.